{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Aileron Therapeutics, Inc. technically bullish or bearish?
As of May 19, 2025, the technical trend has shifted to mildly bearish, driven by bearish daily moving averages and Bollinger Bands, despite some mildly bullish signals from the weekly MACD.
Who are in the management team of Aileron Therapeutics, Inc.?
As of March 2022, the management team of Aileron Therapeutics, Inc. includes Chairman Jeffrey Bailey, CEO Dr. Manuel Aivado, Lead Independent Director Dr. Reinhard Ambros, and Independent Directors William McKee, Jodie Morrison, Nolan Sigal, and Josef von Rickenbach. They oversee the company's strategic direction and operations.
What does Aileron Therapeutics, Inc. do?
Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing stapled peptides for cancer, endocrine and metabolic diseases, and inflammation. It has a market cap of approximately $39.88 million and reported a net profit loss of $6 million as of March 2025.
How big is Aileron Therapeutics, Inc.?
As of Jun 18, Aileron Therapeutics, Inc. has a market capitalization of 39.88 million and reported net sales of 0.00 million with a net profit of -61.27 million over the last four quarters. The balance sheet shows shareholder's funds of 54.39 million and total assets of 69.24 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
